Subscribe or buy profile to access the full content and links. At a glance Development Overview Introduction Key development milestones Drug Properties & Chemical Synopsis Biomarker Trial Landscape Development Status Summary Table Commercial Information ...
We also determined the activity concentrations and specific activity of 90Sr in the teeth of two adult cattle (L-adult-1 and L-adult-2) from area L, that were 22 and 51 months old, respectively, during the FNPP acci- dent. Based on their age, we assumed that development of permanent...
COVID-19 Vaccine Development By leveraging the best use of our past and present research properties, technologies and accumulated R&D knowledge, and in collaboration with external institutions, Daiichi Sankyo researchers in Japan continue their work on developing COVID-19 vaccines. Daiichi Sankyo took ...
June 6, 2024 · 3 min read · Greg Slabodkin Drug Development Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial May 3, 2024 · 2 min read · Tyler Patchen Business BMS, Repertoire Ink Potential $1.8B De...
Basic schemes and databases necessary to assess the radioactive release in severe accidents at nuclear power plants are presented. The approaches include one based on the physical and chemical properties of the core fuel, and another based on the radiati
including oral consumption, intranasal insufflation, injection, and smoking. Overall, data from the Category 1 through Category 3 in vitro and in vivo studies suggest that MorphaBond has properties that are expected to reduce abuse ...
Subscribe or buy profile to access the full content and links. At a glance Development Overview Introduction Company agreements Key development milestones Patent information Drug Properties & Chemical Synopsis Biomarker Trial Landscape Development Status ...
Senter et al., “The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma,” Nature Biotechnology 30(7):631-637 (Jul. 2012). Shen et al., “Conjugation site modulates the in vivo stability and therapeutic activity of...
FIG. 7 A graph showing dissolution properties of tablets coated with various coating agents (dissolution test medium: phosphate buffer solution (pH 6.8)). FIG. 8 A graph showing dissolution properties of tablets coated with hypromellose (dissolution test medium: acetate buffer solutions (pH 4.0) a...
Owing to progress in elucidation of the fact that the regulatory mechanism of apoptosis is often impaired in cancer or immune diseases and also elucidation of the regulatory pathway of apoptosis, the development of a novel apoptosis inducer which can be used in the treatment of cancer or immune ...